Sanofi will invest up to 1.6 billion US dollars to acquire Vicebio and enter the respiratory system field.

According to a statement dated July 22, Sanofi has reached an exclusive final agreement to acquire Vicebio, a biopharmaceutical company that is developing the next generation of respiratory virus vaccines. According to the terms of the agreement, Vicebio shareholders will receive a total of up to $1.6 billion, including $1.15 billion in upfront payments and $450 million in development and regulatory milestone payments, subject to customary conditions.